NCT03632655 is a NA clinical trial of prostate biopsy in Prostate Cancer, sponsored by Weill Medical College of Cornell University.

Who is sponsoring NCT03632655?

NCT03632655 is sponsored by Weill Medical College of Cornell University.

What drugs are being tested in NCT03632655?

Interventions in NCT03632655: prostate biopsy.

What condition does NCT03632655 study?

NCT03632655 studies Prostate Cancer, Elevated PSA.

Is NCT03632655 still recruiting?

NCT03632655 is currently terminated. Last updated 31 May 2024.

Are results published for NCT03632655?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-05-31 · How we verify

NCT03632655

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective, Randomized Trial Comparing Office-based MR-guided Prostate Biopsy Approaches

Terminated NA Results posted Last updated 31 May 2024

What this trial tests

NA trial testing prostate biopsy in Prostate Cancer in 38 participants. Terminated before completion.

Timeline

23 December 2017

Primary endpoint
8 October 2020

8 October 2020

Quick facts

Lead sponsor	Weill Medical College of Cornell University
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	38
Start date	23 December 2017
Primary completion	8 October 2020
Estimated completion	8 October 2020
Sites	1 location across United States

Drugs / interventions tested

prostate biopsy

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Elevated PSA — all drugs for Elevated PSA →

Sponsor

Weill Medical College of Cornell University

Who can join

18 and older, male only, with Prostate Cancer or Elevated PSA. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized trial will compare the safety and efficacy of TPM versus TRUS biopsies performed in the outpatient setting. Primary endpoints will be pain as well as detection of clinically significant disease (defined as Gleason Score \>=7 or cancer core length \>=6 mm). Secondary endpoints will be detection of any prostate cancer, hospital re-admissions within 30 days, aborted procedures due to discomfort, procedure time, adverse events including hematuria, urinary retention, hematospermia, hematochezia, and infection, and patient-reported outcomes as measured on validated instruments such as International Prostate Symptom Scores (IPSS) and International Index of Erectile Function (IIEF-5). In men who subsequently elect to undergo radical prostatectomy for definitive treatment of their prostate cancer, Gleason scores at final pathology will be correlated to the Gleason scores obtained at time of biopsy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of prostate biopsy

Trials testing the same drug.

NCT06691438 — Evaluation of the Effect on Pain of Attentional Diversion Associated with Hypnotic Induction by Virtual Reality (VRH) in · NA · not yet recruiting
NCT06027203 — Transperineal Versus Transrectal Prostate Biopsy · completed
NCT03947515 — Urinary and Prostate Microbiotes and Prostate Cancer · NA · completed
NCT06507462 — A Diagnostic Prediction Model for Prostate Cancer in Patients With PI-RADS Score 3 · completed
NCT02131207 — MRI Before Biopsy in Diagnosing Patients With Prostate Cancer · terminated

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Weill Medical College of Cornell University trials

Trials by the same sponsor.

NCT07485712 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2 · NA · not yet recruiting
NCT05811338 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1 · NA · not yet recruiting
NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT06818734 — Implementation of a Clinical Decision Support Tool for Postpartum Depression · NA · not yet recruiting
NCT07485725 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 3 · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03632655 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Weill Medical College of Cornell University
Last refreshed: 31 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03632655.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing